NOAH Compendium

Printed from NOAH Compendium (https://www.noahcompendium.co.uk). (c) Copyright NOAH Compendium 2024. All Rights Reserved.
Date: Thursday, May 30, 2024 2:33

Release 3.124
Bupaq Multidose 0.3mg/ml Solution for Injection for Dogs and Cats
 
Species: Cats, Dogs
Therapeutic indication: Pharmaceuticals: Neurological preparations: Analgesics
Active ingredient: Buprenorphine
Product:Bupaq Multidose 0.3mg/ml Injection for Dogs and Cats
Product index: Bupaq Multidose Injection for Dogs and Cats
Incorporating:
Presentation
Each ml contains: Active substance: Buprenorphine (as hydrochloride) 0.3 mg and Excipient: Chlorocresol 1.35 mg
Clear colourless to almost colourless solution.
Uses
Dog: Post-operative analgesia. Potentiation of the sedative effects of centrally-acting agents.
Cat: Post-operative analgesia.
Dosage and administration
For intramuscular or intravenous use.
DOG: Post-operative analgesia, potentiation of the sedation
CAT: Post-operative analgesia
10 - 20 micrograms per kg (0.3 - 0.6 ml per 10 kg)
For further pain relief the dose may be repeated if necessary:
DOG: either after 3 ‑ 4 hours with 10 µg/kg or after 5 ‑ 6 hours with 20 µg/kg.
CAT: Once, after 1 - 2 hours with 10 - 20 µg/kg.
While sedative effects are present by 15 minutes after administration, analgesic activity becomes apparent after approximately 30 minutes. To ensure that analgesia is present during surgery and immediately on recovery, the product should be administered preoperatively as part of premedication.
When administered for potentiation of sedation or as part of premedication, the dose of other centrally-acting agents, such as acepromazine or medetomidine, should be reduced. The reduction will depend on the degree of sedation required, the individual animal, the type of other agents included in premedication and how anaesthesia is to be induced and maintained. It may also be possible to reduce the amount of inhalational anaesthetic used.
Animals administered opioids possessing sedative and analgesic properties may show variable responses. Therefore, the response of individual animals should be monitored and subsequent doses should be adjusted accordingly. In some cases, repeat doses may fail to provide additional analgesia. In these cases, consideration should be given to using a suitable injectable NSAID.
An appropriately graduated syringe must be used to allow accurate dosing. The rubber stopper can be punctured a maximum of 25 times.
Contra-indications, warnings, etc
Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not administer by the intrathecal or peridural route. Do not use pre-operatively for Caesarean section (see section 'Pregnancy').
Adverse reactions
Salivation, bradycardia, hypothermia, agitation, dehydration and miosis can occur in the dog, and rarely hypertension and tachycardia.
Mydriasis and signs of euphoria (excessive purring, pacing, rubbing) commonly occur in cats and will usually resolve within 24 hours.
Buprenorphine may cause respiratory depression (refer to section 'Special Precautions for Use in Animals). When used to provide analgesia, sedation is rarely seen, but may occur at dose levels higher than those recommended.
Local discomfort or pain at the injection site, resulting in vocalisation, may occur very rarely*. The effect is normally temporary.
*The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals )
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated reports)
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
Special precautions for use in animals
Use of the veterinary medicinal product in the below circumstances should only be in accordance with the benefit/risk assessment by the responsible veterinarian.
Buprenorphine may cause respiratory depression and as with other opioid drugs, care should be taken when treating animals with impaired respiratory function or animals that are receiving drugs that can cause respiratory depression.
In case of renal, cardiac or hepatic dysfunction or shock, there may be greater risk associated with the use of the product. Safety has not been fully evaluated in clinically compromised cats.
Buprenorphine should be used with caution in animals with impaired liver function, especially biliary tract disease, as the substance is metabolised by the liver and its intensity and duration of action may be affected in such animals.
The safety of buprenorphine has not been demonstrated in animals less than 7 weeks of age.
Repeat administration earlier than the recommended repeat interval suggested in section 'Dosage and administration' is not recommended.
Long-term safety of buprenorphine in cats has not been investigated beyond 5 consecutive days of administration.
The effect of an opioid on head injury is dependent on the type and severity of the injury and the respiratory support supplied..
User warnings
Wash hands/affected area thoroughly after any accidental spillage.
As buprenorphine has opioid-like activity, care should be taken to avoid self-injection. In case of accidental self-injection or ingestion, seek medical advice immediately and show the package leaflet or the label to the physician. Naloxone should be available in case of accidental parenteral exposure. Following eye contamination or skin contact, wash thoroughly with cold running water. Seek medical advice if irritation persists.
Pregnancy
Laboratory studies in rats have not produced any evidence of a teratogenic effect. However, these studies have shown post-implantation losses and early foetal deaths. These may have resulted from a reduction in parental body condition during gestation and in post-natal care owing to sedation of the mothers. As reproductive toxicity studies have not been conducted in the target species, use only according to the benefit/risk assessment by the responsible veterinarian. The product should not be used pre-operatively in cases of Caesarean section, due to the risk of respiratory depression in the offspring periparturiently, and should only be used post-operatively with special care (see below).
Lactation
Studies in lactating rats have shown that, after intramuscular administration of buprenorphine, concentrations of unchanged buprenorphine in the milk equalled or exceeded that in the plasma. As it is likely that buprenorphine will be excreted in the milk of other species, use is not recommended during lactation. Use only according to benefit/risk assessment by the responsible veterinarian.
Interaction with other medicinal products
Buprenorphine may cause some drowsiness, which may be potentiated by other centrally acting agents, including tranquillisers, sedatives and hypnotics.
There is evidence in humans to indicate that therapeutic doses of buprenorphine do not reduce the analgesic efficacy of standard doses of an opioid agonist, and that when buprenorphine is employed within the normal therapeutic range, standard doses of opioid agonist may be administered before the effects of the former have ended without compromising analgesia. However, it is recommended that buprenorphine is not used in conjunction with morphine or other opioid-type analgesics, e.g. etorphine, fentanyl, pethidine, methadone, papaveretum or butorphanol.
Buprenorphine has been used with acepromazine, alphaxalone/alphadalone, atropine, dexmedetomidine, halothane, isoflurane, ketamine, medetomidine, propofol, sevoflurane, thiopental and xylazine. When used in combination with sedatives, depressive effects on heart rate and respiration may be augmented.
Overdose
In cases of overdosage, supportive measures should be instituted, and, if appropriate, naloxone or respiratory stimulants may be used.
When administered at overdose to dogs, buprenorphine may cause lethargy. At very high doses, bradycardia and miosis may be observed.
Naloxone may be of benefit in reversing reduced respiratory rate and respiratory stimulants such as Doxapram are also effective in man. Because of the prolonged duration of effect of buprenorphine in comparison to such drugs, they may need to be administered repeatedly or by continuous infusion. Volunteer studies in man have indicated that opiate antagonists may not fully reverse the effects of buprenorphine. In toxicological studies of buprenorphine hydrochloride in dogs, biliary hyperplasia was observed after oral administration for one year at dose levels of 3.5 mg/kg/day and above. Biliary hyperplasia was not observed following daily intramuscular injection of dose levels up to 2.5 mg/kg/day for 3 months. This is well in excess of any clinical dose regimen in the dog.
Pharmaceutical precautions
Keep out of the sight and reach of children. Keep the vial in the outer carton in order to protect from light. Do not refrigerate or freeze. Do not use after the expiry date stated on the label. Shelf life after first opening the container: 28 days
Legal category
Legal category: POM-V
Packaging quantities
Package sizes: 10 ml, 5 x 10 ml, 10 x 10 ml. Not all pack sizes may be marketed.
Further information
Pharmacodynamic properties
Buprenorphine is a potent, long-acting analgesic acting at opiate receptors in the central nervous system. Buprenorphine can potentiate the effects of other centrally-acting agents, but has, at clinical doses, only a limited sedative effect of its own. Buprenorphine exerts its analgesic effect via high affinity binding to opiate receptors, particularly µ, in the central nervous system. At clinical dose levels, buprenorphine binds with high affinity and high receptor avidity, such that its dissociation from the receptor site is slow. This could account for its longer duration of activity. Buprenorphine has little effect on gastro-intestinal motility.
Pharmacokinetic particulars
Signs of sedation normally appear by 15 minutes. Analgesic effects appear around 30 minutes with peak effects usually being observed at about 1 – 1.5 hours. Following intravenous administration to dogs there is considerable inter-dog variability in pharmacokinetic parameters. The major route of excretion in all species is the faeces. Highest concentrations of drug-related material were observed in liver, lung and brain. Peak levels occurred rapidly and declined to low levels by 24 hours after dosing.
Marketing Authorisation Holder (if different from distributor)
Richter Pharma AG, Feldgasse 19, 4600 Wels, Austria
Marketing Authorisation Number
Vm 22080/4003
Significant changes